Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis

Journal of Experimental Medicine

Volumn 180, Issue 6, 1994, Pages 2173-2179

  Evans, T J ^a   Moyes, D ^a   Carpenter, A ^a   Martin, R ^a   Loetscher, H ^b   Lesslauer, W ^b   Cohen, J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TN3; RECEPTOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CONTROLLED STUDY; IMMUNOTHERAPY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPSIS;

ANIMAL; COMPARATIVE STUDY; ESCHERICHIA COLI INFECTIONS; IMMUNOGLOBULIN G; MICE; MICE, INBRED STRAINS; MOLECULAR WEIGHT; NEUTRALIZATION TESTS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SEPTICEMIA; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TUMOR NECROSIS FACTOR;

EID: 0028043394     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.180.6.2173     Document Type: Article

References (36)

1. Rackow, E.C., and M.E. Astiz. 1991. Pathophysiology and treatment of septic shock. J. Am. Med. /Issue. 266:548.
2. Glauser, M.P., G. Zanetti, J.-D. Baumgartner, and j. Cohen. 1991. Septic shock: pathogenesis. Lancet. 338:732.
3. Tracey, K.J., B. Beutler, S.F. Lowry, J. Merryweather, S. Wolpe, I.W. Milsark, R.J. Hariri, T.J. Fahey III., A. Zentella, J.D. Albert, et al. 1986. Shock and tissue injury induced by recom binant human cachectin. Science (Wash. DC). 234:470.
4. Michie, H.R., K.R. Manogue, D.R. Spriggs, A. Revhaug, S. O’Dwyer, C. Dinarello, A. Cerami, S.M. Wolff, and D.W. Wilmore. 1988. Detection of circulating tumour necrosis factor after endotoxin administration. N. Engl. J. Med. 318:1481.
5. Dinarello, C.A., J.A. Gelfand, and S.M. Wolff. 1993. An ticytokine strategies in the treatment of the systemic inflam matory response syndrome. J. Am. Med. /Issue. 269:1829.
6. Loetscher, H., Y.-C.E. Pan, H.-W. Lahm, R. Gentz, M. Brockhaus, H. Tabuchi, and W. Lesslauer. 1990. Molecular cloning and expression of the human 55kd tumor necrosis factor receptor. Cell. 61:351.
7. Schall, T.J., M. Lewis, K.J. Koller, A. Lee, G.C. Rice, G.H.W. Wong, T. Gatanaga, G.A. Granger, R. Lentz, H. Raab, et al. 1990. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell. 61:361.
8. Smith, C.A., T. Davis, D. And erson, L. Solam, M.P. Beck mann, R. Jerzy, S.K. Dower, D. Cosman, and R.G. Goodwin. 1990. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science (Wish. DC). 248:1019.
9. Dembic, Z., H.R. Loetscher, U. Gubler, Y.-C.E. Pan, H.-W. Lahm, R. Gentz, M. Brockhaus, and W. Lesslauer. 1990. Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine. 2:231.
10. Engelmann, H., H. Holtmann, C. Brakebusch, Y.-S. Avni, I. Sarov, Y. Nophar, E. Hadas, O. Leitner, and D. Wallach. 1990. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol. Chem. 265:14497.
11. Espevik, T., M. Brockhaus, H. Loetscher, U. Nonstad, and R. Shalaby. 1990. Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor. J. Exp. Med. 171:415.
12. Pfeifer, K., T. Matsuyama, T.M. Kiindig, A. Wakeham, K. Kishihara, A. Shahinian, K. Wiegmann, P.S. Ohashi, M. Kronke, and TW. Mak. 1993. Mice deficient for the 55kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73:457.
13. Rothe, J., W. Lesslauer, H. Lotscher, Y. Lang, P. Koebel, F. Kontgen, A. Althage, R. Zinkernagel, M. Steinmetz, and H. Bluethmann. 1993. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection with Listeria monocytogenes. Nature (Lord.). 364:798.
14. Tartaglia, L., R.F. Weber, I.S. Figari, C. Reynolds, M.A. Pal ladino, Jr., and D.V. Goeddel. 1991. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl. Acad. Sci. USA. 88:9292.
15. Tartaglia, L.A., and D.V. Goeddel. 1992. Two TNF receptors. Immunol. Today. 13:151.
16. Eck, M.J., and S.R. Sprang. 1989. The structure of tumor necrosis factor alpha at 2.6 A resolution: implications for receptor binding. J. Biol. Chem. 264:17595.
17. Loetscher, H., R. Gentz, M. Zulauf, A. Lustig, H. Tabuchi, E.-J. Schlaeger, M. Brockhaus, H. Gallati, M. Manneberg, and W. Lesslauer. 1991. Recombinant 55-kDa tumor necrosis factor (TNF) receptor. J. Biol. Chem. 266:18324.
18. Pennica, D., VT. Lam, R.F. Weber, W.J. Kohr, L.J. Basa, M.W. Spellman, A. Ashkenazi, SJ. Shire, and D.V. Goeddel. 1993. Biochemical characterization of the extracellular domain of the 75-kilodalton tumor necrosis factor receptor. Biochemistry. 32:3131.
19. Engelmann, H., D. Novick, and D. Wallach. 1990. Two tumor- necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J. Biol. Chem. 265:1531.
20. Nophar, Y., O. Kemper, C. Brakebusch, H. Engelmann, R. Zwang, D. Aderka, H. Holtmann, and D. Wallach. 1990. Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino-acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO (Eur. Mol. Biol. Organ.) J. 9:3269.
21. Mohler, K.M., D.S. Torrance, C. Smith, R.G. Goodwin, K.E. Stremler, V.P. Fung, H. Madani, and M.B. Widmer. 1993. Soluble tumor necrosis factor (TNF) receptors are effective ther apeutic agents in lethal endotoxemia and function simultane ously as both TNF carriers and TNF antagonists. J. Immunol. 151:1548.
22. Tracey, K.J., Y. Fong, D.G. Hesse, K.R. Manogue, AT. Lee, G.C. Kuo, S.F. Lowry, and A. Cerami. 1987. Anti-cachetine TNF monoclonal antibodies prevent septic shock during le thal bacteraemia. Nature (Lond.). 330:662.
23. Silva, A.T., K.F. Bayston, and J. Cohen. 1990. Prophylactic and therapeutic effects of a monoclonal antibody to tumour necrosis factor-alpha in experimental Gram-negative shock. J. Biol. 162:421.
24. Hackett, S.P., and D.L. Stevens. 1993. Superantigens associated with Staphylococcal and Streptococcal toxic shock syndrome are potent inducers of tumor necrosis factorβ synthesis.J. In fect. Dis. 168:232.
25. Jacobs, C.A., M.P. Beckmann, K. Mohler, C.R. Maliiszewski, W.C. Fanslow, and D.H. Lynch. 1993. Pharmacokinetic parameters and biodistribution of soluble cytokine receptors. Int. Rev. Exp Pathol. 34B:123.
26. Lesslauer, W., H. Tabuchi, R. Gentz, M. Brockhaus, E.J. Schlaeger, G. Grau, P.F. Piguet, P. Pointaire, P. Vassalli, and H. Loetscher. 1991. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur.J J. Immunol. 21:2883.
27. Van Zee, K.J., T. Kohno, E. Fischer, C.S. Rock, L.L. Mol- dawer, and S. Lowry. 1992. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflamma tion and can protect against excessive tumor necrosis factor a in vitro and in vivo. Proc Natl. Acad. Sci. USA. 89:4845.
28. Ashkenazi, A., S.A. Marsters, D.J. Capon, S.M. Chamow, I.S. Figari, D. Pennica, D.V. Goeddel, M.A. Palladino, and D.H. Smith. 1991. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesion. Proc Natl. Acad. Sci. USA. 88:10535.
29. Angehrn, P., D. Banner, T. Braun, A. dArcy, G. Gehr, R. Gentz, F. Mackay, E.-J. Schlaeger, H. Schoenfeld, H. Loetscher, and W. Lesslauer. 1993. Two distinct tumor necrosis factor receptors in health and disease. In Tumor Necrosis Factor: Mo lecular and Cellular Biology and Clinical Relevance. W. Fiers and W.A. Buurman, editors. Karger, Basel. 33-39.
30. Echtenacher, B., W. Falk, D.N. Mannel, and P.H. Krammer. 1990. Requirement of endogenous tumor necrosis factor/ cachectin for recovery from experimental peritonitis. J. Immunol. 145:3762.
31. Flick, D.A., and G.E. Gifford. 1984. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J. Immunol. Methods. 68:167.
32. Brockhaus, M., H.-J. Schoenfeld, H.-J. Schlaeger, W. Hun- ziker, W. Lesslauer, and H. Loetscher. 1990. Identification of two kinds of TNF receptors on human cell lines by mono clonal antibodies. Proc Natl. Acad. Sci. USA. 87:3127.
33. Evans, T.J., E. Strivens, A. Carpenter, and j. Cohen. 1993. Differences in cytokine response and induction of nitric oxide synthase in endotoxin-resistant and endotoxin-sensitive mice after intravenous Gram-negative infection. J. Immunol. 150:5033.
34. Evans, T., A. Carpenter, A. Silva, and J. Cohen. 1992. Differen tial effects of monoclonal antibodies to tumor necrosis factor alpha and gamma interferon on induction of hepatic nitric oxide synthase in experimental Gram-negative sepsis. Infect. Immun. 60:4133.
35. Aderka, D., H. Engelmann, Y. Maor, C. Brakebusch, and D. Wallach. 1992. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp Med. 175:323.
36. Tartaglia, L.A., D. Pennica, and D.V. Goeddel. 1993. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signalling by the 55-kDa TNF receptor. Proc. Natl. Acad. Sci. USA. 268:18542